Literature DB >> 9262935

Meta-analysis of erythrocyte Na,K-ATPase activity in bipolar illness.

S W Looney1, R S el-Mallakh.   

Abstract

Sodium, potassium-activated adenosine triphosphatase (Na,K-ATPase) pump activity has been variously reported to be increased, decreased, or unchanged in bipolar patients. To explore this association we conducted a meta-analysis of the available literature. All papers containing data on erythrocyte Na,K-ATPase activity were reviewed independently by both authors. A meta-analysis of these data was accomplished by standard procedure. We found a significant mood-state-related decrease in Na,K-ATPase activity in both manic and bipolar depressed patients when compared to euthymic bipolar patients, but not when ill patients were compared to normal controls. The overall change can be characterized as small to moderate in magnitude.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9262935     DOI: 10.1002/(sici)1520-6394(1997)5:2<53::aid-da1>3.0.co;2-6

Source DB:  PubMed          Journal:  Depress Anxiety        ISSN: 1091-4269            Impact factor:   6.505


  26 in total

Review 1.  Endogenous digitalis-like Na+, K+-ATPase inhibitors, and brain function.

Authors:  D Lichtstein; H Rosen
Journal:  Neurochem Res       Date:  2001-09       Impact factor: 3.996

2.  Repeated electroconvulsive shock induces changes in high-affinity [3H]-ouabain binding to rat striatal membranes.

Authors:  Magda Bignotto; Marco Antonio Campana Benedito
Journal:  Neurochem Res       Date:  2006-05-09       Impact factor: 3.996

3.  Na+/K+-ATPase level and products of lipid peroxidation in live cells treated with therapeutic lithium for different periods in time (1, 7, and 28 days); studies of Jurkat and HEK293 cells.

Authors:  Miroslava Vosahlikova; Lenka Roubalova; Hana Ujcikova; Martina Hlouskova; Stanislav Musil; Martin Alda; Petr Svoboda
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-02-21       Impact factor: 3.000

4.  Psychiatric disorders in rapid-onset dystonia-parkinsonism.

Authors:  Allison Brashear; Jared F Cook; Deborah F Hill; Alethea Amponsah; Beverly M Snively; Laney Light; Niki Boggs; Cynthia K Suerken; Mark Stacy; Laurie Ozelius; Kathleen J Sweadner; W Vaughn McCall
Journal:  Neurology       Date:  2012-08-29       Impact factor: 9.910

5.  Frontal lobe bioenergetic metabolism in depressed adolescents with bipolar disorder: a phosphorus-31 magnetic resonance spectroscopy study.

Authors:  Xian-Feng Shi; Douglas G Kondo; Young-Hoon Sung; Tracy L Hellem; Kristen K Fiedler; Eun-Kee Jeong; Rebekah S Huber; Perry F Renshaw
Journal:  Bipolar Disord       Date:  2012-07-20       Impact factor: 6.744

6.  The sensitivity of Na+, K+ ATPase as an indicator of blood diseases.

Authors:  Abulnaja Kkalid Omar; Kherd Ali Ahmed; Nawal Mohammed Helmi; Kumosani Taha Abdullah; Mohamad H Qarii; Huwait Etimad Hasan; Albukhari Ashwag; Alaama Mohammed Nabil; Al-Ghamdi Maryam Abdu; Moselhy Said Salama
Journal:  Afr Health Sci       Date:  2017-03       Impact factor: 0.927

7.  Nanomolar ouabain augments Ca2+ signalling in rat hippocampal neurones and glia.

Authors:  Hong Song; Scott M Thompson; Mordecai P Blaustein
Journal:  J Physiol       Date:  2013-01-07       Impact factor: 5.182

8.  Evaluation of citrate synthase activity in brain of rats submitted to an animal model of mania induced by ouabain.

Authors:  Tiago P Freitas; Gislaine T Rezin; Cinara L Gonçalves; Gabriela C Jeremias; Lara M Gomes; Giselli Scaini; Brena P Teodorak; Samira S Valvassori; João Quevedo; Emilio L Streck
Journal:  Mol Cell Biochem       Date:  2010-04-07       Impact factor: 3.396

Review 9.  A review of MR spectroscopy studies of pediatric bipolar disorder.

Authors:  D G Kondo; T L Hellem; X-F Shi; Y H Sung; A P Prescot; T S Kim; R S Huber; L N Forrest; P F Renshaw
Journal:  AJNR Am J Neuroradiol       Date:  2014-02-20       Impact factor: 3.825

Review 10.  The behavioral actions of lithium in rodent models: leads to develop novel therapeutics.

Authors:  Kelley C O'Donnell; Todd D Gould
Journal:  Neurosci Biobehav Rev       Date:  2007-04-13       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.